The World Health Organization (WHO) fact sheet on Chronic Obstructive Pulmonary Disease (COPD) provides an overview of this common lung condition characterized by persistent respiratory symptoms and airflow limitation.
The World Health Organization (WHO) fact sheet on Chronic Obstructive Pulmonary Disease (COPD) provides an overview of this common lung condition characterized by persistent respiratory symptoms and airflow limitation.
The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state, prevention of disease progression and minimization of symptoms. So far no validated questionnaires are available to measure symptom ...and functional state in daily clinical practice. The aim of this study was to develop and validate the Clinical COPD Questionnaire (CCQ).
more
The article "Under- and over-diagnosis of COPD: a global perspective" reviews the worldwide variation in the prevalence of chronic obstructive pulmonary disease (COPD) and issues related to its misdiagnosis. It highlights that COPD is under-diagnosed due to factors such as limited access to spiromet...ry and variable diagnostic criteria, especially in low- and middle-income countries. Conversely, over-diagnosis often results from reliance on non-standard criteria or inadequate spirometry use. The article discusses key risk factors, including age, gender, exposure to pollutants, and comorbidities, and emphasizes the need for standardized diagnostic practices to better address and manage COPD globally.
more
The document "COPD 101: Understanding the Basics" from the COPD Foundation provides foundational knowledge about chronic obstructive pulmonary disease (COPD). It explains what COPD is, common symptoms, risk factors, diagnosis methods, and treatment options, including medications and lifestyle change...s. The guide emphasizes early diagnosis and management to help patients live healthier lives and prevent disease progression.
more
The document "COPD 101: Understanding the Basics" from the COPD Foundation provides foundational knowledge about chronic obstructive pulmonary disease (COPD). It explains what COPD is, common symptoms, risk factors, diagnosis methods, and treatment options, including medications and lifestyle change...s. The guide emphasizes early diagnosis and management to help patients live healthier lives and prevent disease progression.
more
Chronic respiratory diseases, such as asthma and
chronic obstructive pulmonary disease, kill more than
four million people every year and affect hundreds
of millions more. These diseases erode the health
and well-being of the patients and have a negative
impact on families and societies. Women ...and
children are particularly vulnerable, especially those
in low and middle income countries, where they are
exposed on a daily basis to indoor air pollution from
solid fuels for cooking and heating. In high income
countries, tobacco is the most important risk factor
for chronic respiratory diseases, and in some of
these countries, tobacco use among women and
young people is still increasing.
more
Background: Asthma and chronic obstructive pulmonary disease (COPD) cause a considerable burden of morbidity
and mortality in low-income and middle-income countries (LMICs). Access to safe, effective, quality-assured, and
affordable essential medicines is variable. We aimed to review the existing ...literature relating to the availability, cost,
and affordability of WHO’s essential medicines for asthma and COPD in LMICs.
more
The article investigates the global burden and risk factors of chronic obstructive pulmonary disease (COPD). It emphasizes that COPD is a leading cause of morbidity and mortality worldwide, with significant health and economic impacts. The study identifies smoking as the primary risk factor, but als...o highlights other contributors such as occupational exposure, air pollution, and respiratory infections. The authors discuss variations in COPD prevalence and mortality rates across different regions, influenced by socioeconomic and environmental factors. The article calls for comprehensive public health strategies to reduce exposure to risk factors and improve early diagnosis and management to curb the global impact of COPD.
more
Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme...nt. Inhaler therapy (eg, aerosolised medications by inhalation, nebulisation, or propellant) is the mainstay of treatment for COPD and asthma. Adherence to maintenance medications for COPD and asthma results in improved lung function and quality of life, as well as decreased hospitalisation and mortality. WHO have included short-acting beta-agonists, long-acting muscarinic antagonists, and inhaled corticosteroids on the essential medications list, with a target goal of achieving 80% availability of these medications in public and private facilities. However, despite these efforts, accessibility, and affordability of medications for COPD and asthma remains scarce.
more
The article from The Lancet Global Health discusses the "silent epidemic" of chronic obstructive pulmonary disease (COPD) in Africa, emphasizing its status as an under-recognized yet significant health issue. Although COPD is the third leading cause of death globally, it remains largely overlooked i...n African countries. The article highlights studies indicating varying prevalence rates of COPD across sub-Saharan Africa, with major risk factors including tobacco smoking and biomass smoke exposure. The findings suggest that COPD in Africa often affects younger age groups (30–40 years), likely due to early exposure to biomass smoke. The author calls for better education and training for healthcare providers and urges policymakers to address COPD through improved surveillance and effective prevention and treatment strategies.
more
The article "The silent epidemic of COPD in Africa" discusses the under-recognized yet significant prevalence of chronic obstructive pulmonary disease (COPD) in Africa. Despite being the third leading cause of death worldwide, COPD remains poorly studied and largely unknown in sub-Saharan Africa. Th...e article highlights risk factors such as tobacco smoking and biomass smoke exposure, which significantly affect both men and women. Biomass smoke, in particular, is linked to COPD in younger individuals and impacts women due to prolonged exposure during cooking. The piece calls for better awareness, training for healthcare providers, and proactive measures to address and manage COPD in the region.
more
Cardiovascular disease, diabetes, chronic obstructive pulmonary disease, cancers, and other non-communicable diseases are among the leading causes of morbidity and mortality in low-income, middle-income, and high-income countries, and The Lancet Taskforce recently made the case for investing in non-...communicable disease prevention. Now, in The Lancet Planetary Health, Benjamin Bowe and colleagues report that exposure to PM2·5 air pollution is indeed a risk factor for diabetes.
more
The website for the COPD Foundation in South Africa provides information and resources dedicated to raising awareness, improving education, and supporting individuals affected by Chronic Obstructive Pulmonary Disease (COPD). Managed by the C.A.R.E.S. Group (COPD Advocacy, Research, Education, Suppor...t), the site aims to advocate for better COPD management and care. It includes guidance for patients, caregivers, and healthcare professionals, along with updates on research, events, and programs to enhance COPD treatment and support throughout South Africa.
more
Aerosol pollutants are known to raise the risk of development of non-communicable respiratory diseases (NCRDs) such as asthma, chronic bronchitis, chronic obstructive pulmonary disease, and allergic rhinitis. Sub-Saharan Africa’s rapid pace of urbanization, economic expansion, and population growt...h raise concerns of increasing incidence of NCRDs. This research characterizes the state of research on pollution and NCRDs in the 46 countries of Sub-Saharan Africa (SSA). This research systematically reviewed the literature on studies of asthma; chronic bronchitis; allergic rhinitis; and air pollutants such as particulate matter, ozone, NOx, and sulfuric oxide.
more
Elderly people are at a higher risk of COVID-19 infection due to their decreased immunity and body reserves, as well as multiple associated comorbidities like diabetes, hypertension, chronic kidney disease and chronic obstructive pulmonary disease. Also, course of disease tends to be more severe in ...case of elderlies resulting in higher mortality.
more
The World Health Organization (WHO) highlights the significant health risks associated with household air pollution, primarily resulting from the use of inefficient and polluting fuels and technologies for cooking, heating, and lighting. In 2020, approximately 2.1 billion people—about one-third of... the global population—relied on open fires or inefficient stoves fueled by kerosene, biomass (such as wood, animal dung, and crop waste), and coal. This exposure led to an estimated 3.2 million deaths, including over 237,000 deaths of children under the age of five. The pollutants emitted from these sources contribute to a range of health issues, including respiratory infections, heart disease, stroke, chronic obstructive pulmonary disease, and lung cancer. The WHO emphasizes the urgent need for transitioning to cleaner fuels and technologies to mitigate these health risks.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
Accessed on 06.03.2022
Air pollution is contamination of the indoor or outdoor environment by any chemical, physical or biological agent that modifies the natural characteristics of the atmosphere. Household combustion devices, motor vehicles, industrial facilities and forest fires are common sou...rces of air pollution. Pollutants of major public health concern include particulate matter, carbon monoxide, ozone, nitrogen dioxide and sulfur dioxide. Outdoor and indoor air pollution cause respiratory and other diseases and is an important source of morbidity and mortality.
Air pollution kills an estimated seven million people worldwide every year. WHO data shows that almost all of the global population (99%) breathe air that exceeds WHO guideline limits containing high levels of pollutants, with low- and middle-income countries suffering from the highest exposures. WHO is supporting countries to address air pollution.
From smog hanging over cities to smoke inside the home, air pollution poses a major threat to health and climate. The combined effects of ambient (outdoor) and household air pollution cause millions of premature deaths every year, largely as a result of increased mortality from stroke, heart disease, chronic obstructive pulmonary disease, lung cancer and acute respiratory infections.
Website
more
El objetivo es proveer al equipo de salud, una guía de diagnóstico y terapéutica clínica, tanto farmacológica como no farmacológica, con recomendaciones basadas en evidencia de la mejor calidad disponible y adaptada al marco local.
Los usuarios de la Guía son todos los integrantes del ...equipo de salud y responsables de la atención de personas con EPOC (médicos, kinesiólogos, nutricionistas, psicólogos, enfermeros, educadores para la salud y otros); estudiantes de grado de todas las carreras vinculadas a la salud; proveedores, administradores y financiadores de servicios de salud; responsables de equipos de atención de la EPOC
y funcionarios de la salud pública.
more